Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
<br><strong>Background<br></strong> Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are licenced for initiation for glucose lowering in people with type 2 diabetes (T2DM) with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2). However, recent trial data...
主要な著者: | Hinton, W, Feher, MD, Munro, N, Joy, M, de Lusignan, S |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
BioMed Central
2021
|
類似資料
-
Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
著者:: William Hinton, 等
出版事項: (2021-06-01) -
Does renal function or heart failure diagnosis affect primary care prescribing for sodium-Glucose co-transporter 2 inhibitors in type 2 diabetes?
著者:: Hinton, W, 等
出版事項: (2020) -
Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
著者:: Hinton, W, 等
出版事項: (2020) -
How generalizable are cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors? A national database study: study protocol
著者:: Hinton, W, 等
出版事項: (2019) -
Disparities in prescribing of sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP-4 inhibitors in people with Type 2 diabetes and chronic kidney disease (CKD)
著者:: Shah, S, 等
出版事項: (2018)